Covid-19: current knowledge, disease potential, prevention and clinical advances.
COVID-19
antivirals
financial crisis
mortality rate
transmission rate (Ro)
vaccines
Journal
Turkish journal of biology = Turk biyoloji dergisi
ISSN: 1303-6092
Titre abrégé: Turk J Biol
Pays: Turkey
ID NLM: 9434434
Informations de publication
Date de publication:
2020
2020
Historique:
entrez:
30
6
2020
pubmed:
1
7
2020
medline:
1
7
2020
Statut:
epublish
Résumé
The top priority of any nation is to lead the nation towards prosperity, progress, and economic growth, confronting several challenges and concerns arisen from global situations. The sudden outbreak of any disease defies the health care systems and economy of nations. COVID-19 is one of the viral diseases which broke out in Wuhan city of China in 2019. COVID-19 outbreak intermittently prevailed all over the world. It exposes the fragility of the established health care systems across the world in spite of comprising modern science and technology. Unfortunately, there is no chemotherapeutic agent in the regimen of antiviral drugs or no vaccine available to curb this infectious disease. As a consequence, this deadly infection has prevailed all over the world. The antiviral drugs used for viral diseases excluding COVID-19 infection are Ramdesvir, Favipiravir, and Ribavarin, and antimalarial agents (Chloroquine & Hydroxychloroquine) are being administered to the patients for redemption of this infection. Fortunately, these existing drugs have been found clinically active and are being used. In this review, we present the current scenario and status of epidemiology, diagnosis, treatment, vaccine development for COVID-19, and its impact on the socio-economic structure.
Identifiants
pubmed: 32595349
doi: 10.3906/biy-2005-29
pmc: PMC7314501
doi:
Types de publication
Journal Article
Langues
eng
Pagination
121-131Informations de copyright
Copyright © 2020 The Author(s).
Déclaration de conflit d'intérêts
CONFLICT OF INTEREST: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
Chem Asian J. 2019 Nov 18;14(22):3962-3968
pubmed: 31389664
Biosaf Health. 2019 Sep;1(2):84-90
pubmed: 32501444
Virol Sin. 2018 Feb;33(1):104-107
pubmed: 29500691
N Engl J Med. 2020 Mar 5;382(10):929-936
pubmed: 32004427
Antiviral Res. 2015 Apr;116:76-84
pubmed: 25666761
Lancet. 2020 Feb 15;395(10223):497-506
pubmed: 31986264
Antiviral Res. 2015 Mar;115:9-16
pubmed: 25542975
Lancet. 2020 Feb 15;395(10223):507-513
pubmed: 32007143
Virus Res. 2017 Jan 15;228:7-13
pubmed: 27840112
Nature. 2014 Apr 17;508(7496):402-5
pubmed: 24590073
J Med Virol. 2020 May 21;:
pubmed: 32437080
Lancet. 2020 Feb 15;395(10223):514-523
pubmed: 31986261
Antimicrob Agents Chemother. 2014;58(1):120-7
pubmed: 24145548
Lancet. 2020 Feb 22;395(10224):565-574
pubmed: 32007145
J Virol. 2010 Mar;84(5):2511-21
pubmed: 20032190
Clin Microbiol Rev. 2015 Apr;28(2):465-522
pubmed: 25810418
Clin Microbiol Rev. 2007 Oct;20(4):660-94
pubmed: 17934078
Cell Res. 2020 Mar;30(3):269-271
pubmed: 32020029
Nat Rev Drug Discov. 2016 May;15(5):327-47
pubmed: 26868298
Biophys J. 2016 Mar 8;110(5):1028-32
pubmed: 26958878
Nat Med. 2013 Oct;19(10):1313-7
pubmed: 24013700
Trials. 2018 Jan 30;19(1):81
pubmed: 29382391
J Gen Virol. 2014 Mar;95(Pt 3):571-577
pubmed: 24323636
Nat Rev Drug Discov. 2020 Mar;19(3):149-150
pubmed: 32127666
Chembiochem. 2020 Mar 2;21(5):730-738
pubmed: 32022370
Nat Commun. 2020 Jan 10;11(1):222
pubmed: 31924756
Antiviral Res. 2006 Sep;71(2-3):90-5
pubmed: 16820225
Nat Rev Microbiol. 2016 Aug;14(8):523-34
pubmed: 27344959
Antiviral Res. 2014 Oct;110:94-103
pubmed: 25108173
J Gastroenterol Hepatol. 2016 Jan;31(1):180-9
pubmed: 26110395
J Med Virol. 2020 Apr;92(4):441-447
pubmed: 31994742
PLoS Pathog. 2011 Oct;7(10):e1002331
pubmed: 22046132
Antimicrob Agents Chemother. 2015 Feb;59(2):1088-99
pubmed: 25487801
Viruses. 2015 Sep 29;7(10):5206-24
pubmed: 26426038
Biomed Pharmacother. 2017 Jul;91:1152-1159
pubmed: 28531943
Antivir Ther. 2016;21(5):455-9
pubmed: 26492219
Antiviral Res. 2018 Feb;150:123-129
pubmed: 29258862